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Purpose: This study investigates the efficacy of an intravitreal gas injection in inducing a 
posterior vitreous detachment (PVD) in patients with clinically significant diabetic macular 
edema refractory to laser therapy.
Methods: A local ethics committee-approved technique of an intravitreal injection of pure 
perfluoropropane gas (C3F8) was performed for all participants. After a period of prone posi-
tioning, the patients underwent regular and detailed clinical review.
Main outcome measures: The induction of a PVD, change in macular thickness, change 
in visual acuity.
Results: A PVD was induced in all five eyes with subsequent signs of reduction in macular 
thickness and resolution of exudates. Mean visual improvement was 11 ETDRS (Early Treatment 
Diabetic Retinopathy Study) letters (range 4–21). Apart from a transient vitreous hemorrhage 
in one eye, there were no significant treatment-related complications.
Conclusion: The induction of a PVD by pneumatic retinopexy appears to have a significant 
influence on diabetic macular edema in eyes which have not successfully responded to macular 
laser therapy. A randomized clinical trial is justified on the basis of the initial promising data.
Keywords: optical coherence tomography, OCT, posterior vitreous detachment, 
perfluoropropane
Introduction
Diabetic retinopathy is the commonest cause of blindness in patients of working age in 
developed countries, principally due to the complications of neovascularization, or to 
maculopathy (focal or diffuse macular edema).1,2 Although considerable progress has 
been made in reducing the incidence of blindness through improved medical control, 
screening, and timely laser therapy,3–6 many patients with maculopathy are either 
relatively resistant to photocoagulation, or develop recurrent edema, with consequent 
visual deterioration despite undergoing repeat laser therapy.7 Reported outcomes from 
vitreoretinal surgery for macular edema have been relatively disappointing, with the risk 
of sight-threatening side effects arising from such a complex procedure.8,9   Intravitreal 
steroids and anti-vascular endothelial growth factor (anti-VEGF) preparations are 
increasingly employed, but there is also a recognized morbidity and a requirement 
for repeated injections.10,11
It is likely that the pathogenesis of diabetic macular edema is due to a complex 
interaction of a number of factors, and these include vitreoretinal relationships at the 
macula. Specifically, it seems that an attached vitreous may tend to sustain or exacer-
bate edema, while conversely a posterior vitreous detachment (PVD) may ameliorate Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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  existing retinopathy.12,13 These observations provided the 
rationale for the current study, whereby a technique of intra-
vitreal gas injection was employed to evaluate its effect on 
diabetic macular edema through the induction of a PVD.
Methods
The study design was of an open label, nonrandomized, 
prospective trial. A detailed protocol was submitted to and 
agreed by the local ethics committee. All patients provided 
fully informed consent before enrolment in the study.
Inclusion criteria were:
•	 Medically diagnosed diabetes (type I or II);
•	 Clinically significant macular edema (CSMO), accord-
ing to the Early Treatment Diabetic Retinopathy Study 
(ETDRS) guidelines:14
○	 Retinal thickening within 500 µm of the center of the 
fovea;
○	 Hard, yellow exudates within 500 µm of the center 
of the fovea with adjacent retinal thickening;
○	 At least 1 disc area of retinal thickening, any part of 
which is within 1 disc diameter of the center of the 
fovea;
•	 Four or more previous macular laser treatments;
•	 No significant macular ischemia on fluorescein 
angiography;
•	 An attached vitreous (including vitreomacular traction), 
identified by biomicroscopy and B scan ultrasonography;
•	 No untreated retinal pathology (retinal breaks, significant 
degeneration, etc).
Exclusion criteria were:
•	 Epimacular membrane;
•	 Macular hole;
•	 Atrophic macular degeneration;
•	 Proliferative diabetic retinopathy;
•	 Inability to provide informed consent.
Pre-treatment investigations included visual acuity 
(ETDRS chart), biomicroscopy, fluorescein angiography, 
and optical coherence tomography (OCT) scanning (Stratus 
OCT, Zeiss Meditec, Jena, Germany); mydriasis of the treat-
ment eye was accomplished with cyclopentolate 1% drops. 
  Povidone iodine 5% was applied around the affected eye and 
to the conjunctival sac. A volume of 0.3 mL of 100% perfluo-
ropropane (C3F8) gas was then injected into the vitreous cavity 
at 3.5–4.0 mm posterior to the limbus via a 27-gauge needle. 
The central retinal artery was visualized with an indirect 
ophthalmoscope and 20 dioptre lens. If it was observed to be 
occluded following gas injection, paracentesis was performed. 
The intraocular pressure was measured after 20 minutes. 
Topical maxitrol and cyclopentolate 1% drops (Alcon, Fort 
Worth, TX) were prescribed (and the appropriate hypoten-
sive agent if there was an elevation in intraocular pressure), 
and the patient instructed to posture in a prone position for 
40 minutes in each hour for 1 week.
Post-treatment evaluation was performed at 1 week, 
1 month, 3 months, and 4–6 monthly thereafter. At each 
visit, visual acuity was measured and dilated biomicroscopy 
performed, together with OCT scanning. The central foveal 
thickness was used for analysis. Color fundus photography 
was also performed, but fluorescein angiography only if bio-
microscopy and OCT findings provided insufficient informa-
tion for an adequate evaluation. A minimum of 3 months was 
allowed to gauge the effect of the gas injection. A PVD was 
judged to have developed if there was a visible Weiss ring 
and/or posterior hyaloid face (PHF). B scan ultrasonography 
was performed in equivocal cases. If there was persistent 
CSMO by 3 months, consideration was given to administering 
additional therapy (laser, or intravitreal injection).
Results
Due to the strict inclusion and exclusion criteria for this 
study, only five eyes of five patients were recruited over a 
2-year period. All patients had type II diabetes, with a mean 
age of 69 (range 64–83) and mean review was 18 months 
(range 9–36). A PVD was induced in all eyes, with unequivo-
cal vitreomacular separation being observed between 1 week 
and 1 month following injection in all cases. None of the 
patients treated had prior vitreomacular traction (although 
the efficacy of this method for this condition has been 
indicated in another publication by the authors.15 Signs of 
reduction in macular thickness and early resorption of exu-
dates were observed by 1 month, with the beneficial trend 
continuing for 9–12 months following treatment. Median 
visual improvement and macular thickness was 11 ETDRS 
letters (range 4–21) and 157 µm respectively (Table 1 and 
Figures 1–3). No eyes lost vision over the review period 
due to persistent or recurrent macular edema. Apart from 
a transient vitreous hemorrhage in one eye at 1 month 
(patient 2, possibly due to minor retinal vascular trauma 
during vitreous separation), there were no significant retinal 
treatment-related complications. In those eyes which were 
phakic, there was no observed progression of lenticular 
opacities. Although no patient required further macular laser 
therapy over the period of review, one patient (patient 5) 
developed an area of peripheral neovascularization 9 months 
following gas injection, and panretinal photocoagulation 
was performed.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Figure 1 Patient 1. Color fundus photographs and fluorescein angiograms (A and 
B) before and (C and D) 9 months following pneumatic retinopexy.
Note: Gradual resolution of the macular exudates (with no further laser therapy 
during this time).
Discussion
The influence of the vitreoretinal relationship in diabetic 
macular edema has been long recognized,12,13 and pars plana 
vitrectomy has been employed to induce a PVD and peel the 
inner limiting membrane, or any associated epiretinal mem-
brane. The observed postoperative improvement in macular 
status has however been mitigated by such side effects as 
cataract formation, retinal breaks, and retinal detachment.8,9 
There are also logistical considerations with this technique 
in that it requires access to specialized facilities and must be 
performed by a vitreoretinal specialist. In many regions and 
countries, there are insufficient resources to allow the ready 
availability of this form of treatment.
Previous studies have commented on the   effectiveness of 
pneumatic retinopexy in inducing a PVD for the   treatment 
Pre gas injection3  months post injection
9 months post injection 17 months post injection
Figure 2 Patient 2. Color fundus photographs before and following pneumatic 
retinopexy.
Note:  Macular exudates have resolved without further laser or other therapy.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Figure 3 Patient 2. OCT images (A) prior to gas injection and (B) 17 months following pneumatic retinopexy. reduction in macular thickness: 359 microns.
Note: separation of posterior hyaloid face (arrowed).
Abbreviation: OCT, optical coherence tomography.
1.0 mm
229 284
322
258
S
T
90°
N
I
329 270
309
281
264
3.00 mm
6.00 mm
Map diameters
Microns
Center
Total volume
219 +/− 17 microns
7.59 mm3
01 00 2003 00 4005 00µm
OCT image Fundus image
BClinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1547
intravitreal gas injection and diabetic macular edema
of macular holes and in cases of nonproliferative diabetic 
retinopathy, with consequent beneficial effects on the 
pathology.16,17 In the current study, the observed resolu-
tion of exudates and edema in these refractory cases was 
  remarkable. Although the previous laser treatments might 
have had some beneficial effect, this may have been counter-
acted by persistent vitreoretinal traction, on which laser treat-
ment alone would have had no significant influence. Apart 
from relief of traction, induction of a PVD may also confer a 
secondary beneficial effect in increasing retinal oxygenation 
derived from the fluid phase between the neuroretina and 
the PHF. An increase in oxygen tension within the inner 
retina could have a mitigating effect on macular edema by 
a number of mechanisms: reduced VEGF production caus-
ing decreased retinal vascular permeability; autoregulatory 
arteriolar vasoconstriction reducing hydrostatic pressure 
in capillaries and venules. There will be in turn decreased 
extravascular fluid flow (the Starling equation) and reduced 
edema formation.18
One notable feature of the current and of these previous 
studies utilizing gas injection is the low complication rate and 
in particular the absence of retinal tear or detachment forma-
tion, compared with pars planavitrectromy and indeed pneu-
matic retinopexy for established retinal detachment.19,20
In comparison with a vitrectomy, the relative safety of 
gas injection may relate to the gas having a gradual effect 
in separating the PHF from the retina, in the absence of 
preexisting peripheral retinal pathology (inducing a more 
“physiological” PVD).
Pneumatic retinopexy for an established retinal detach-
ment confers compressive and tractional forces on vitreous 
and retina, which are already (at least partially) detached and 
as a consequence, secondary break formation is commonly 
observed, often at sites diametrically opposed to the original 
break location. A different situation is present when gas is 
injected into an eye where there is no PVD and no preexist-
ing peripheral retinal pathology. Induction of a PVD in this 
instance is more analogous to the formation of a spontaneous 
PVD, which is typically associated with a risk of break for-
mation of the order of 10% and a much lower risk of retinal 
detachment.21 In the current series, the high frequency of 
clinical review would in any case have identified any fresh 
retinal break formation, allowing its timely management 
(although to date this has not occurred).
The low numbers of eyes treated in this series reflects the 
cautious approach that was taken to a novel application of 
an established technique in eyes with advanced retinopathy. 
The promising results of this pilot series, together with the 
low complication rate now encourages the establishment of 
a randomized trial to test further the authors’ hypothesis and 
arguably the incorporation of pneumatic retinopexy in com-
bination therapy with laser photocoagulation and intravitreal 
steroid and anti-VEGF injection.
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